At a glance
During this COCA Call, subject matter experts will present an overview of COVID-19 and influenza testing and therapeutic options, including eligibility, indications, and other considerations such as drug interactions.
Overview
Though underutilized, antiviral treatment can prevent progression to severe disease from COVID-19 and influenza, regardless of vaccination status, which is especially important for people who are at higher risk of serious complications. Diagnostic tests are available to guide clinical decision-making and appropriate treatment for these viral respiratory diseases. During this COCA Call, subject matter experts will present an overview of COVID-19 and influenza testing and therapeutic options, including eligibility, indications, and other considerations such as drug interactions.
Presenters
Pragna Patel, MD, MPH
Chief Medical Officer
Coronavirus and Other Respiratory Viruses Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Tim Uyeki, MD, MPH, MPP
Chief Medical Officer
Influenza Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Call Objectives
COCA Call Objectives
At the conclusion of the session, the participant will be able to accomplish the following:
- Cite background information on the topic covered during the presentation.
- Discuss CDC's role in the topic covered during the presentation.
- Describe the topic's implications for clinicians.
- Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
- Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.
Activity-Specific Objectives
- Describe recommended antivirals for treating COVID-19 and influenza and clinical benefits.
- Cite factors for deciding who receives treatment for COVID-19 and influenza.
- Outline indications for testing before starting treatment for COVID-19 and influenza.
- Review available treatment options for COVID-19 and influenza among different populations.
Additional Resources
Influenza
- Guide for considering influenza testing when influenza viruses are circulating in the community | CDC
- Rapid Influenza Diagnostic Tests | CDC
- Testing and Management Considerations for Nursing Home Residents with Acute Respiratory Illness Symptoms when SARS-CoV-2 and Influenza Viruses are Co-circulating | CDC
- Clinical Guidance for Hospitalized and Non-Hospitalized Patients When SARS-CoV-2 and Influenza Viruses are Co-Circulating | CDC
- Clinical Guidance for Patients with Acute Respiratory Illness Being Hospitalized When SARS-CoV-2 and Influenza Viruses are Co-Circulating | CDC
- Clinical Guidance for Patients with Acute Respiratory Illness Not Being Hospitalized When SARS-CoV-2 and Influenza Viruses are Co-Circulating | CDC
- Laboratory Information for Collection of Respiratory Specimens for Influenza Virus Testing | Influenza (Flu) | CDC
- Overview of Influenza Testing Methods | CDC
- Multiplex Assays Authorized for Simultaneous Detection of Influenza Viruses and SARS-CoV-2 by FDA | Influenza (Flu) | CDC
- Clinical Signs and Symptoms of Influenza | CDC
- Influenza Diagnostic Tests | FDA
- Influenza Antiviral Medications: Summary for Clinicians | CDC
COVID-19
- COVID-19 Treatment Clinical Care for Outpatients | COVID-19 | CDC
- Overview of Testing for SARS-CoV-2 | COVID-19 | CDC
- Guidance for SARS-CoV-2 Rapid Testing in Point-of-Care Settings | COVID-19 | CDC
- COVID-19 Testing (hhs.gov)
- Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC
- COVID-19 Vaccination Provider Requirements and Support | CDC
- COVID-19 Data & Surveillance
- Information for Pediatric Healthcare Providers | COVID-19 | CDC
- Underlying Conditions and the Higher Risk for Severe COVID-19 | COVID-19 | CDC
- Clinical Considerations for Special Populations | COVID-19 | CDC
- Treatment Options for COVID19 | HHS/ASPR
- FDA COVID-19 therapeutics
- Test to Treat
- Treatment Locator (hhs.gov)Resources to Prepare for Flu, COVID-19, and RSV | CDC
- IDSA Guidelines on the Treatment and Management of Patients with COVID-19 (idsociety.org)
- Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 1) | Annals of Internal Medicine (acpjournals.org)
- Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 2) | Annals of Internal Medicine (acpjournals.org)
Continuing Education
Instructions for Obtaining Continuing Education (CE)
To receive continuing education (CE) for WC4520R-101024— Updates on Diagnostic Testing and Outpatient Treatment for COVID-19 and Influenza, please visit CDC TRAIN and search for the course in the Course Catalog using WC4520R-101024. Follow the steps below by November 11, 2024. The registration code is COCA101024.
To receive continuing education (CE) for WD4520R-101024— Updates on Diagnostic Testing and Outpatient Treatment for COVID-19 and Influenza, please visit CDC TRAIN and search for the course in the Course Catalog using WD4520R-101024. Follow the steps below between November 12, 2024, and November 12, 2026.
- Register for and complete the course.
- Pass the post-assessment at 75%.
- Complete the evaluation.
- Visit Your Learning to access your certificates and transcript.
ACCREDITATION STATEMENTS
In support of improving patient care, The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CME: The Centers for Disease Control and Prevention designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA CME: Credit Designation Statement – LiveThe Centers for Disease Control and Prevention has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
CNE: The Centers for Disease Control and Prevention designates this activity for 1 nursing contact hours.
CPE: The Centers for Disease Control and Prevention designated this Knowledge-based event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is JA4008229-0000-24-043-L04-P and enduring JA4008229-0000-24-146-H04-P.
CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEUs for this program.
CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 1 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 1. Continuing Competency credits available are 1. CDC provider number 98614.
AAVSB/RACE: This program has been submitted (but not yet approved) for 1 hours of continuing education credit in jurisdictions which recognize AAVSB RACE approval; however, participants should be aware that some boards have limitations on the number of hours accepted in certain categories or restrictions on certain methods of delivery of continuing education.
For Certified Public Health Professionals (CPH): The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credits for this program.
DISCLOSURE: In compliance with continuing education requirements, all planners and presenters/moderators must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.
CDC, our planners, and presenters/moderators wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Content will not include any discussion of the unlabeled use of a product or a product under investigational use.
CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.
Target Audience
- Physicians
- Nurses
- Pharmacists
- Veterinarians
- Physician Assistants
- Health Educators
- Other Clinicians
Additional Information
- Contact Information: coca@cdc.gov
- Support/Funding: Centers for Disease Control and Prevention, Office of Emergency Risk Communication
- Method of Participation: You may participate in the educational activity by viewing the program information above.